Blueprint Medicines Corporation: Business Overview, Financials & Competitive Analysis
Blueprint Medicines Corporation scores 8/10 on the AskCyborg Cyborg Score (Strong). High-growth specialty biotech with lead asset capturing rare disease market, acquired by Sanofi for validated value and pipeline potential. Blueprint demonstrated robust Q1 2025 financial results with AYVAKIT net product revenues reaching $149.4M, representing 61% year-over-year growth. The company has achieved significant commercial traction with its first-in-class asset and.
What is Blueprint Medicines Corporation's industry? Blueprint Medicines Corporation (blueprintmedicines.com) operates in Biotechnology - Specialty Pharma & Rare Diseases. AskCyborg classifies Blueprint Medicines Corporation under Biotechnology - Specialty Pharma & Rare Diseases in its company registry.
Blueprint Medicines is a Cambridge, Massachusetts-based biotechnology company focused on precision therapies for genomically defined cancers, certain blood disorders and immunology. The company's lead asset is Ayvakit...
Cyborg Score thesis
High-growth specialty biotech with lead asset capturing rare disease market, acquired by Sanofi for validated value and pipeline...
Read the full analyst-debate transcript →Get the Latest Blueprint Medicines Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBlueprint Medicines Corporation Overview
Pro stress-test →Blueprint Medicines is a Cambridge, Massachusetts-based biotechnology company focused on precision therapies for genomically defined cancers, certain blood disorders and immunology. The company's lead asset is Ayvakit/Ayvakyt, the only approved medicine for advanced and indolent systemic mastocytosis, which generated $479M in revenue in 2024 and showed 60% year-over-year growth in Q1 2025.
Strategic Profile
Pro stress-test →Strong AYVAKIT demand and expanded market reach fuel revenue growth, while a diversified pipeline and efficient cost structure reduce reliance on a single product and support long-term earnings growth. Notably, Sanofi agreed to acquire Blueprint Medicines for $129.00 per share in cash ($9.1B total), plus potential contingent value rights payments worth up to $6 per share, bringing the total potential value to $9.5B.
Competitive Landscape
Pro stress-test →AYVAKIT is the only approved medicine for advanced and indolent systemic mastocytosis, providing a differentiated position in the rare disease immunology space. Competitors in adjacent rare disease and oncology segments include Gilead Sciences (focused on oncology and immunology) and Roche (broad therapeutic portfolio including targeted therapies). Blueprint's niche positioning in mast cell biology provides limited direct competition.
Industry Context
Blueprint Medicines Corporation operates in Biotechnology - Specialty Pharma & Rare Diseases.
Key facts
Founded: 2008 · Headquarters: Cambridge, US · Employees: N/A · Revenue: $0.56B (TTM as of April 2026) · Market cap: N/A